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ABSTRACT: 54 
Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) and PACAP-Related Peptide (PRP) 55 
are structurally similar peptides encoded in the same transcripts. Their transcription has been 56 
detected not only in the brain but also in a wide range of peripheral tissues, even including organs 57 
of the immune system. PACAP exerts pleiotropic activities through G-protein coupled membrane 58 
receptors: the PACAP-specific PAC-1 and the VPAC-1 and VPAC-2 receptors that exhibit similar 59 
affinities for the Vasoactive Intestinal Peptide (VIP) and PACAP. Recent findings added PACAP 60 
and its receptors to the growing list of mediators that allow cross-talk between the nervous, 61 
endocrine and immune systems in fish. In this study the expression of genes encoding for PACAP 62 
and PRP, as well as VIP/PACAP receptors was studied in laboratory-reared brown trout (Salmo 63 
trutta) after septicaemic infections. Respectively Viral Haemorrhagic Septicaemia Virus (VHSV-Ia) 64 
or the Gram-negative bacterium Yersinia ruckeri (ser. O1 – biot. 2) were used in infection 65 
challenges. Kidney and spleen, the teleost main lymphopoietic organs, were sampled during the first 66 
two weeks post-infection. RT-qPCR analysis assessed specific pathogens burden and gene 67 
expression levels. PACAP and PRP transcription in each organ was positively correlated to the 68 
respective pathogen burden, assessed targeting the VHSV-glycoprotein or Y. ruckeri 16S rRNA. 69 
Results showed as the transcription of PACAP splicing variants and VIP/PACAP receptors is 70 
modulated in these organs during an acute viral and bacterial septicaemic infections in brown trout. 71 
These gene expression results provide clues as to how the PACAP system is modulated in fish, 72 
confirming an involvement during active immune responses elicited by both viral and bacterial 73 
aetiological agents. However, further experimental evidence is still required to fully elucidate and 74 
characterize the role of PACAP and PRP for an efficient immune response against pathogens. 75 
 76 
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1. Introduction 85 
Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) is a pleiotropic neuropeptide 86 
associated with a number of physiological processes. Endocrine, metabolic, gastrointestinal and 87 
immune modulatory effects are known in mammals [1–3]. It was discovered from ovine 88 
hypothalamus due to its ability to stimulate cyclic Adenosine Mono Phosphate (cAMP) synthesis in 89 
rat anterior pituitary cells [4]. PACAP belongs to the secretin/glucagon family of peptides. PACAP 90 
has two molecular forms resulting from post-translational process, PACAP of 38 amino acids 91 
(PACAP-38) and the shorter peptide of 27 residues (PACAP-27) [4,5]. PACAP was recently 92 
identified in a wide range of chordates, including protochordates, fish, amphibians, birds, and 93 
mammals [6–9]. The sequence of PACAP has been remarkably well preserved from tunicate to 94 
human; by contrast, PRP is moderately conserved. The high conservation of PACAP nucleotide 95 
sequence indicates this peptide fulfils an important biological function in a broad spectrum of 96 
organisms [1]. In fish, PRP and PACAP are encoded on the same gene, but alternative splicing 97 
processes render a full length mRNA containing both genes isoforms (PRP/PACAP) together with a 98 
transcript in which exon 4 (PRP) is lacking [6,10–12]. As in mammals, in teleost fish mediates 99 
Growth Hormone (GH) and Gonadotropin release in the pituitary gland [13], and is an important 100 
hypophysiotropic factor [14]. The majority of studies on the biological functions of PACAP in fish 101 
have mainly focused on growth or reproduction among the pleiotropic physiological functions of 102 
PACAP, for example, its growth-promoting effects in African catfish Clarias gariepinus [15] and 103 
Atlantic cod Gadus morhua [16]. Fish PRP, formerly known as GH-Releasing Hormone (GHRH)-104 
like, are less studied and research has been focus mainly in PRP role in GH-releasing activity in the 105 
pituitary gland [10]. More recent findings explore PRP roles also in growth [15] and reproduction 106 
[9,17]. In fish, PACAP and PRP were initially isolated from sockeye salmon Oncorhynchus nerka 107 
[11] and subsequently from many other species, including Atlantic cod [18], catfish Ictalurus 108 
punctatus [19,20], and C. gariepinus [15], zebrafish Danio rerio [21], sturgeon Ascipenser 109 
transmontanus, whitefish Coregonus clupeaformis, arctic grayling Thymallus arcticus, Yellowtail 110 
flounder Pleuronectes ferrugineus, Atlantic halibut Hippoglossus hippoglossus [22] and several 111 
other salmonids [12]. 112 
PACAP exerts multiple activities through G-protein-coupled receptors composed of several 113 
transmembrane domains. It binds to a specific receptor called PAC-1 and additionally to VPAC-1 114 
and VPAC-2 receptors, which also bind Vasoactive Intestinal Peptide (VIP) with an equal affinity. 115 
These receptors are widely distributed in the organism, a feature allowing PACAP to exert a wide 116 
range of effects [23]. On the other hand, PRP receptor, formerly referred to as GHRH-receptor, has 117 
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been isolated only in goldfish Carassius auratus, zebrafish, Fugu and blue gourami Trichogaster 118 
trichopterus [13,24,25]. 119 
Little is known of the expression pattern of PACAP alternative splicing variants in different fish 120 
tissues. Even less is known about the expression of PACAP ligands and receptors, or their function, 121 
in the fish immune system. The different anatomical distribution found for PACAP transcriptional 122 
splicing variants and VIP/PACAP receptors in rainbow trout Oncorhynchus mykiss lymphoid 123 
tissues suggests the existence of diverse mechanisms of regulation of immune functions in fish 124 
mediated by the VIP/PACAP system [26]. Recent discoveries, using immune reactivity assays and 125 
recombinant proteins have added PACAP and its receptors to the growing list of mediators allowing 126 
a functional cross-talk between the nervous, endocrine and immune system in fish [27–29]. Fish 127 
PACAP modulate cytokine synthesis in carp Ctenopharyngodon idella [30], japanese flounder 128 
Paralichthys olivaceus [29] and rainbow trout [31]. Such evidence suggests that PACAP might 129 
directly regulate fish immune cells, acting to promote antiviral/antibacterial immunity. Treatments 130 
with recombinant PACAP (isolated from African catfish) improve salmonids survival after viral 131 
infections. An even better protection is conferred when administered in conjunction with antiviral 132 
drugs (e.g. Ribavirin) [32]. Further experimental data are required to fully characterise the role of 133 
PACAP during immune responses to heterologous pathogens in fish. 134 
Viral Haemorrhagic Septicaemia (VHS), an OIE notifiable listed disease caused by a 135 
Novirhabdovirus (VHSV), is world-wide regarded as one of the most economically important threat 136 
for wild and cultured fish, resulting in high morbidity and mortality [33–35]. Despite decades of 137 
effort vaccines against VHSV are not yet available for commercial use. Fish Yersiniosis or Enteric 138 
Red Mouth disease (ERM), caused by the Gram negative bacteria Yersinia ruckeri, is a major 139 
bacterial disease posing a threat to trout aquaculture [36,37]. ERM vaccines are commercially 140 
available for aquaculture use, but have limited effectiveness to the motile serovar O1 biotype 1, in 141 
development for other biotypes [38,39]. Due to the recent emergence of new bacterial strains the 142 
disease is still widespread in many countries from Europe to North America, as well as South 143 
Africa and Australia [40,41]. Biotype 2 variants of the bacterium, characterized by the concomitant 144 
loss of motility and secreted lipase activity [41–43], were considered an emergent disease for both 145 
American and European salmonid aquaculture, causing outbreaks even in previously vaccinated fish 146 
[41,44]. 147 
In this study, the expression of genes encoding for PACAP splicing variants and VIP/PACAP 148 
receptors, was studied in laboratory-reared specific-pathogen-free (SPF) brown trout Salmo trutta, 149 
the European native trout species. New exon-skipping primers were developed and RT-qPCR 150 
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assays compared the specific gene transcription levels. Transcriptomic analysis revealed their 151 
physiologic expression in central and peripheral immune-organs. Their expression modulation was 152 
studied during VHS and Yersiniosis, known to typically elicit quick TH1-like responses [45], in 153 
kidney and spleen, sampled from infected fish during the first two weeks of infection. The 154 
respective virus or bacteria burden was correlated to the PACAP splicing variants and affine 155 
receptors expression modulation (using GLM analysis). Results from this study provide further 156 
evidence to support the theory of an active involvement of PACAP pathways during an efficient 157 
immune response. 158 
 159 
2. Materials and Methods 160 
2.1 Fish maintenance and experimental design 161 
Triploid brown trout Salmo trutta, were kept under SPF conditions in a recirculation system at 16ºC 162 
(CEFAS, Weymouth, England). Routine bacteriological, virological and parasitological 163 
examinations confirmed the absence of known pathogens. Fish, kept in a 12 h light/ 12 h dark 164 
photoperiod (~ 200 lux at water surface, with 30 min dusk and dawn), were fed 1% bodyweight/day 165 
with a standard commercial trout pellet diet (No. 45 Elite Trout Slow Sinking Food, Skretting). 166 
Twenty brown trout (mean weight 69.5 g ± 16.4 g) were randomly allocated to 30 l tanks, with 167 
three replicate tanks for each treatment group. The water temperature was gradually reduced to 168 
12°C (5 days prior to pathogen challenge), to increase fish susceptibility to VHSV [46], but was 169 
maintained at 16ºC for the bacterial challenge, a temperature considered optimal for ERM 170 
pathogenesis [43]. 171 
 172 
2.2 Infection challenge assessment of pathogen burden  173 
VHSV infection challenge was carried out as previously described [45], with VHSV-Ia (isolate UK-174 
J167, highly pathogenic for rainbow trout [47]) at 5.56x10
5
 TCID50/ml for 4 h at 12ºC. The water 175 
volume was halved and flow suspended for 4 h, keeping oxygen saturation at > 80%. For the mock-176 
exposed group the same procedure was used but with an equal amount of sterile transport medium 177 
used to suspend the virus (Glasgow minimum essential medium, SAFC Biosciences), added to the 178 
tanks. 179 
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Yersinia ruckeri infection was carried out as for the viral challenge, but with a suspension of 180 
serotype O1 biotype 2, isolate UK-06041 (RD6), at 2.7x10
7
 CFU/ml. This isolate is highly 181 
pathogenic for Atlantic salmon and rainbow trout, and was used to characterize the new isolates 182 
virulence [43,48]. The mock-exposed group had instead added sterile Dulbecco’s phosphate 183 
buffered saline (Sigma-Aldrich) added, used to suspend the bacteria. 184 
Five brown trout were sampled at days 1, 3, 7 and 14 p.i. from each of the triplicate treatment tanks. 185 
Kidney and spleen tissues were dissected aseptically and stored in RNAlater (Ambion). Additional 186 
healthy tissues, including gills, thymus, mid-gut and liver were sampled from mock-exposed groups 187 
after 1 day. 188 
VHSV was confirmed by virology screening on monolayers of Epithelioma papulosum cyprini 189 
(EPC) cells as described previously [49]. The growth of any bacteria was checked with kidney and 190 
spleen swabs onto Tryptone Soya Agar (TSA, Oxoid) plates. Y. ruckeri was confirmed with 191 
bacteriology screening and by means of a commercial monoclonal antibody agglutination test 192 
(Mono-Yr, Bionor, Norway). Experimental infection experiments were conducted in accordance 193 
with the current UK animal-welfare regulations. 194 
 195 
2.3 Total RNA extraction and cDNA synthesis 196 
Total RNA was extracted using TRI-reagent (Sigma-Aldrich), as described previously [45]. Tissues 197 
were lysed with two 3 mm diameter Tungsten Carbide Beads (Qiagen), for 3 min at 30 Hz, in a 198 
bench mixer TissueLyserII (Qiagen). No DNase treatment was applied. The RNA pellet was diluted 199 
in TE buffer (10 mM Tris HCl; 1 mM EDTA, pH 8.0). RNA purity and concentration were 200 
determined using a NanoDrop ND-1000 (Thermo Scientific). RNA was stored at -80°C until use. 5 201 
µg of total RNA were converted into cDNA using Oligo-dT28VN (Sigma-Aldrich) primers and 202 
RevertAid Reverse Transcriptase (Fermentas), following the manufacturer’s instructions. cDNA 203 
was diluted with TE buffer and stored at -20°C until use. 204 
 205 
2.4 RT-qPCR assays 206 
For each tissue sample RT-qPCR was performed by adding to 4 μl cDNA template 1μl of each 207 
forward and reverse primer (10 μM) and 14 μl of master mix. The latter was made with Immolase 208 
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(Bioline), SYBR Green ﬂuorescent tag (Invitrogen), dNTPs mix (Bioline), ImmoBuffer (Bioline), 209 
following the manufacturer’s instructions. Assays were performed in technical duplicates in 96-well 210 
plates (Roche), using a LightCycler 480 Real-Time PCR System (Roche). General cycling 211 
conditions were: 10 min at 95°C, followed by 45 cycles with denaturation (94°C, 30 s), annealing 212 
(62°C (Ta), 30 s) and elongation (72°C, 20 s (Te)); 1 min of melting temperature (Tm) recording at 213 
84°C. RT-qPCR assays also measured specific pathogen burdens, viral or bacterial, in tissues (Tab. 214 
1). VHSV-Ia burden was measured by targeting the transmembrane glycoprotein (G) gene (F/R-215 
1028 [50]), while bacterial burden targeted the Y. ruckeri 16S rRNA [51]. 216 
 217 
2.5 Optimization of gene transcription detection 218 
Available rainbow trout Oncorhynchus mykiss PACAP splicing variants and VIP/PACAP receptor 219 
nucleotide sequences were retrieved from the National Centre for Biotechnology Information 220 
(NCBI) (www.ncbi.nlm.nih.gov/). Multiple sequence alignments were generated using 221 
CLUSTALW2 (www.ebi.ac.uk/Tools/msa/clustalw2/). Intron-exon boundaries for brown trout 222 
PACAP and PRP genes was predicted aligning rainbow trout PACAP (AF343977, lacking exon 4) 223 
and PRP (AF343976) to the Atlantic salmon Salmo salar whole genome shotgun (WGS) contigs 224 
AGKD01043834. WGS contigs were obtained with the BLAST/BLAT search tool, with default 225 
options, from Ensembl Genome Browser (http://www.ensembl.org/). A similar approach was used 226 
for the VIP/PACAP receptors, retrieved by aligning the O. mykiss sequences, PAC-1 (AY706216), 227 
VPAC-1 (AY706218) and VPAC-2 (AY706217), respectively to contigs CAAK05042347, 228 
CABZ01001604 and CABZ01032844 from zebrafish Danio rerio WGS. Exon-skipping primers 229 
were specifically designed using Primer3Plus (www.bioinformatics.nl/primer3plus/). Genomic 230 
DNA amplification was excluded by designing at least one primer crossing an intron-exon 231 
boundary. Primer sequences were analysed for hairpin structures, self and hetero-dimers using the 232 
online oligonucleotide properties calculator OligoCalc 233 
(www.basic.northwestern.edu/biotools/OligoCalc.html). Conventional PCR tests with brown trout 234 
genomic DNA and cDNA templates verified that no genomic amplification occurred. Amplicons 235 
were purified with Gel/PCR Purification Kit (Biomiga), following the manufacturer’s instructions. 236 
Sequences were obtained from Eurofins MWG Operon's sequencing service (Ebersberg 237 
Laboratories, Germany). Product specificity was assured by BLAST search 238 
(www.blast.ncbi.nlm.nih.gov/Blast.cgi). The efficiency of each primer pair was calculated by 239 
means of a calibration curve, using 10-fold serial dilutions in TE buffer from a 1 nM solution of 240 
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purified amplicon. Amplification efficiency was calculated with the LightCycler Software (Roche). 241 
Each selected primer pair had specifically optimised Ta, Te, and Tm for RT-qPCR (Tab. 1). 242 
 243 
2.6 Gene expression data analysis 244 
Tissues from 6 mock-exposed fish, sampled at day 1 p.i., were used to assess the constitutive 245 
transcription of PACAP splicing variants and VIP/PACAP receptors. Their transcription 246 
modulation was assessed in kidney and spleen tissues from 6-7 fish from each treatment group at 247 
each time point. RT-qPCR assays were always performed in duplicate for each sample. The 248 
inclusion of two dilutions enabled the relative quantification, and transcript level was calculated 249 
using the LightCycler 480 (Roche) integrated software. Specific gene expression was normalised to 250 
the expression of a reference gene, S. trutta Elongation Factor-1α (EF-1α). The fold change 251 
between each infected group and respective unexposed control was calculated at each time point. 252 
Normalised individual fold change values were anchored to the lowest value recorded in each data 253 
set and then Log2 transformed, as described previously [52]. Specific pathogen burden was 254 
similarly assessed, from each kidney and spleen cDNA sample (Fig. 2), as described previously 255 
[53]. 256 
 257 
2.7 Statistical analysis 258 
The significance of the average fold change between uninfected and infected groups was analysed 259 
by one-way analysis of variance (ANOVA) and LSD post hoc test for comparison of group means. 260 
Differences were considered statistically significant when p < 0.05. The degree of the correlation 261 
between specific pathogen burden and host gene expression was calculated by parametric 262 
correlation analysis, as approached in previous fish infection studies [53]. The Pearson product-263 
moment correlation coefficient r was considered significant at p < 0.05 (2-tailed). A General Linear 264 
Model (GLM) for analysis of the covariance assessed the significance of the factorial interaction 265 
between individual gene expression and individual pathogen burden in relation to day post infection 266 
[Time], used as covariate. The interaction was considered significant at p < 0.05. Statistical 267 
analyses were performed with SPSS
®
 Statistics package version 20.0 (IBM Corporation) and 268 
graphically represented using GraphPad Prism version 5.04 (GraphPad Software Inc.). 269 
 270 
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3. Results 271 
3.1 Brown trout gene confirmation 272 
Each amplicon was sequenced to confirm primers specificity to target mRNA. Sequences were 273 
verified as the brown trout homologue. All selected primers had amplification efficiency ≥ 1.91 and 274 
gave no sensitive amplification when used on genomic DNA. For this purpose primers were tested 275 
on gDNA from brown trout, giving same results also on gDNA from rainbow trout and Atlantic 276 
salmon. Sequences were deposited in the GenBank database under Accession Numbers: HG000281 277 
for PACAP, HG000280 for PRP/PACAP, HG000282 for PAC-1, HG000283 for VPAC-1 and 278 
HG000284 for VPAC-2. Additionally, PRP intron 4 sequence was obtained and deposited in the 279 
GenBank database under Acc. No. HG000279. A common reverse primer was designed to both 280 
PACAP and PRP splicing variants, named as “PRP/PACAP-R”, but exclusively used for PACAP 281 
detection. The reverse primer for specific PRP transcription detection (named as “PRP-R2”) was 282 
instead designed between exon 4 and 5 boundaries, thus skipping intron 4. A summary of optimised 283 
primers and RT-qPCR conditions for genes screened during this study is provided in Table 1. 284 
 285 
3.2 Constitutive expression of PACAP splicing variants and PAC-1, VPAC-1 and 286 
VPAC-2 receptors 287 
The study of PACAP ligands constitutive expression showed a detectable transcription in all the 288 
organs tested (Fig. 1.A). Generally a higher constitutive transcription was found for PRP when 289 
compared to PACAP. Both PACAP splicing variants showed their highest physiologic expression 290 
in the gut. The expression of PACAP and PRP receptors was instead more variable. Whilst PAC-1, 291 
VPAC-1 and VPAC-2 constitutive transcription was also detectable in all the organs tested (Fig. 292 
1.B), a relatively high transcript level was seen for PAC-1 in immune tissues but not in liver which 293 
in contrast had highest VPAC-1 expression. VPAC-2 had the highest expression in the mid-gut, 294 
spleen and kidney (average Cq in control group ranging between 22.5 to 24.1). 295 
 296 
 297 
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3.3 Experimental infection and assessment of pathogen burdens 298 
Experimental infection with VHSV-Ia was confirmed by the appearance CPE during virology tests, 299 
indicating a successful experimental infection of the SPF brown trout. Fish from the mock-300 
challenged group showed no mortality or disease symptoms, no appreciable viral titres and no fish 301 
had detectable bacteria. VHS pathognomonic clinical signs were observed, including acute 302 
petechial haemorrhages in many organs, including skin, brain, heart, liver, spleen, kidney 303 
(pronephros and mesonephros), trunk muscle, intestine and perivisceral abdominal adipose tissue. 304 
VHS gave sporadic mortalities, reaching a total of 4.9% at 2 weeks p.i., with the first event recorded 305 
at day 8. VHSV-Gp detection in kidney and spleen showed a higher burden at day 3 p.i., gradually 306 
decreasing thereafter (Fig. 2.A). Cross-correlation of the viral burden in kidney and spleen 307 
suggested a quick and even distribution of the virus during the septicaemic infection (r = 0.927). 308 
Experimental infection with Yersinia ruckeri (serotype O1 biotype 2) was confirmed with 309 
diagnostic tests, indicating a successful experimental infection of the SPF brown trout. No other 310 
bacterial infections were detected in any experimental fish. All mock-infected fish were negative. 311 
ERM pathognomonic clinical signs were observed, including lethargy, skin darkening, and 312 
anorexia. Erythema at the base of the pectoral fins, spiralling within the tanks, strong darkening 313 
followed by mortality were also seen in the most advanced stages. The ERM typical reddening 314 
around the mouth was only sporadically observed in brown trout. At the necropsy, fish showed 315 
typical lesions due to bacterial haemorrhagic septicaemia, with a marked inflammatory response in 316 
all tissues. However, mortality was low, with a cumulative mortality of 12.1% during the 2 weeks 317 
trial, with the first death recorded at day 6 p.i.. The bacterial septicaemic spreading was confirmed 318 
by the detection of Y. ruckeri 16S rRNA at each time point in both tissues (Fig. 2.B), with a peak at 319 
day 7 p.i., and a rapid decrease thereafter. 320 
 321 
3.4 Comparative analysis of PACAP splicing variants during septicaemic infection 322 
The expression of PACAP was rapidly (within 1 day) modulated in both kidney and spleen in 323 
response to VHSV-Ia infection (Fig. 3.A). The highest level of induction was found in spleen, with 324 
a 143 fold-increase at day 3 p.i.. A gradual decrease in transcript level followed to the end of the 325 
experiment at day 14 p.i. but it remained significantly upregulated in spleen. PRP showed a 326 
radically differential response to VHS (Fig. 3.C), where a delayed and selective induction was seen 327 
in spleen. In contrast ERM stimulated the transcription of both PACAP and PRP. By day 1 p.i. both 328 
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transcripts were strongly upregulated in spleen, reaching a 132 and 29 fold-increase respectively 329 
(Fig. 3.B). PACAP transcription was more sustained in the spleen at all sampling points, when 330 
compared to kidney. A similar selective induction was seen for PRP in spleen during the early 331 
stages of the infection (Fig 3.D). Cross correlation analyses between the expression of PACAP and 332 
PRP showed a significant positive relationship, with a higher coefficient for spleen in both diseases: 333 
during VHS, in kidney r = 0.464 while in spleen r = 0.606; during ERM, in kidney r = 0.553 while 334 
in spleen r = 0.727. PACAP and PRP expression in kidney and spleen was positively correlated to 335 
the VHSV infection marker. However their upregulation was significantly correlated to time p.i. 336 
only in spleen (Table 2). PACAP expression was also positively correlated to the bacterial burden in 337 
both tissues and a significant interaction with time p.i. was found. PRP expression had a significant 338 
correlation with time p.i. in spleen only. 339 
 340 
3.5 Comparative analysis of VIP/PACAP receptors expression during septicaemic 341 
infections 342 
Comparative expression profiles of PACAP receptors showed that the three receptors were 343 
differentially regulated, but mainly in the kidney (Fig. 4). A high individual variance confounded 344 
the analysis due to private response patterns. The expression of PAC-1, the PACAP and PRP 345 
specific receptor, showed a strong down-regulation at day 1 p.i. in spleen during ERM. Indeed 346 
PAC-1 expression was negatively correlated to bacterial burden in spleen, confirmed by the co-347 
variance analysis (Table 2). However, PAC-1 showed a delayed upregulation in kidney during VHS 348 
and in both kidney and spleen during ERM (Fig 4.A and .B). During VHS PAC-1 expression was 349 
influenced (significantly) by time in kidney. Few changes were detected for VPAC-1 expression 350 
between infected and non-infected brown trout, despite some significant differences being apparent 351 
between kidney and spleen at day 1 p.i. during both infections (Fig. 4.C and .D). However, a 352 
significant correlation of VPAC-1 expression with time p. i. was found for both tissues during VHS 353 
(Table 2). In contrast, VPAC-2 showed an initial downregulation in both kidney and spleen 1 day 354 
post VHSV-Ia infection, followed by a small increase in kidney at day 3 and day 14 p.i. (Fig. 4.E). 355 
VPAC-2 was also negatively correlated to VHSV burden in spleen and its expression was 356 
significantly correlated to time p.i. (Table 2). During ERM, VPAC-2 showed a large induction in 357 
kidney from day 1 to day 14 p.i., with no significant modulation occurring in spleen (Fig. 4.F). In 358 
agreement with this expression pattern VPAC-2 was positively correlated with bacterial burden and 359 
time post-infection in the kidney (Table 2). 360 
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4. Discussion 361 
One characteristic of the salmonid PRP/PACAP precursor gene is the phenomenon of exon-362 
skipping, often observed in non-mammalian vertebrates such as teleosts but not in mammals [22]. 363 
In this study, we investigated the differential expression of the two PACAP splicing variants by RT-364 
qPCR in two brown trout immune tissues post-infection. Specific oligonucleotides were optimised 365 
to independently amplify both PACAP and PRP, and showed that the highest expression of both 366 
transcripts was found in the mid-gut. The expression of these transcripts in the intestine and pyloric 367 
caecum has been previously shown for sockeye salmon [12] and rainbow trout [26]. It is known in 368 
mammals that PACAP stimulates histamine release from enterochromaffin cells through activation 369 
of L-type calcium channels in the gastric mucosa [1,54]. Additionally, the PACAP involvement in 370 
the control of gut mobility and secretion was also demonstrated in Atlantic cod [18], and recent 371 
studies have established a connection between PRP/PACAP mRNA expression in the intestine of P. 372 
olivaceus and possible immune functions in the gut [29]. Interestingly, the entire PRP/PACAP 373 
precursor mRNAs are induced in the intestine and pyloric caecum of olive flounder within 1 h post-374 
challenge with challenge with Edwardsiella tarda, reaching their highest level 24 h post-challenge, 375 
suggesting that PRP and PACAP may act as regulators of the immune system, especially in the 376 
gastrointestinal tract. 377 
In this study, PRP and PACAP mRNA was detected in both central (thymus) and peripheral 378 
(spleen) lymphoid organs. In mammals, PACAP and its receptors are expressed by immune cells 379 
[55,56]. PACAP positive cells and PACAP mRNA expression is detected in the thymus, spleen and 380 
lymph nodes of rats [56]. In teleosts, PACAP splicing variants are present in the spleen of tilapia 381 
Oreochromis mossambicus [57], rainbow trout [26] and darkbarbel catfish Pelteobagrus vachelli 382 
[58]. The spleen is one of the major lymphoid organs of teleosts, also involved in hematopoiesis, 383 
although its role is generally limited to erythropoiesis and thrombopoiesis [59,60]. 384 
PACAP and PRP were also detected in gills. It is well known in fish that the mucous surfaces of 385 
skin and gills constitute a first barrier against pathogens. In zebrafish using in situ hybridization, the 386 
first T cell receptor (TcRα) positive cells outside the thymus are found in the intestine and gills at 387 
day 9 post fertilization [61]. In rainbow trout, only PACAP was detected in the gills [26], and both 388 
were absent from kidney and liver unlike the results of the present study. Indeed, PACAP 389 
expression has not been previously detected in kidney [20,21,26,28,58,62]. Then again, mRNA 390 
expression in the liver was detected before in darkbarbel catfish [58], but not in channel catfish 391 
[20], tilapia [57] and rainbow trout [26]. These differences could be explained because of the lower 392 
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sensitivity of conventional PCR [20,28,62] or the exon-skipping phenomenon of the PRP/PACAP 393 
precursor gene, which some evidence suggests is a regulatory mechanism that may differ by 394 
species, even in the same lineage. The promoter region possessing regulatory elements for gene 395 
expression is quite divergent between species, suggesting that while the coding region of the 396 
PACAP gene is well-conserved throughout vertebrates, the transcriptional regulation has evolved 397 
and developed in a species-specific manner [29]. 398 
Assessment of the constitutive expression of teleost VIP/PACAP receptors has been performed 399 
previously and showed a widespread distribution throughout the body [26,58,63–66]. For example, 400 
in the darkbarbel catfish PAC-1 was detectable at various levels in all tissues studied (including 401 
brain, gill, intestine, liver, muscle, ovary, testis, stomach, spleen) except the gills [58]. Recently, the 402 
expression of rainbow trout PAC-1, VPAC-1 and VPAC-2 receptors was assessed by RT-qPCR 403 
[27]. PAC-1 receptor mRNA was detected in brain, gills, intestine, head kidney, spleen, blood and 404 
skin. VPAC-1 receptor mRNA was detected in brain, intestine, spleen and blood but not in gills, 405 
head kidney or skin, and lastly, VPAC-2 receptor mRNAwas detected in brain, gills, intestine, 406 
spleen and skin but not in head kidney or blood. No mRNAs for any of the genes were detectable in 407 
liver and gonads [26]. The latter contrasts with our study in brown trout, where a clear expression of 408 
VPAC-1 and VPAC-2 was seen in liver. 409 
The wide distribution of PACAP splicing variants and VIP/PACAP receptors in various tissues in 410 
brown trout is similar to that in mammals [1,26], suggesting an involvement of PACAP and VIP 411 
peptides in a broad spectrum of biological functions in these organisms. Besides the presence of 412 
PACAP and its receptors in fish immune-related tissues, the immunoregulatory role of PACAP in 413 
teleosts has been investigated recently in catfish, tilapia, rainbow trout, olive flounder and grass 414 
carp [26–32] but further studies are warranted. In contrast to PACAP, the biological role of PRP has 415 
still to be fully elucidated. PRP was previously termed GHRH or GHRH-like peptide, and was 416 
considered the mammalian GHRH homolog in non-mammalian vertebrates due to its ability to 417 
stimulate GH release from pituitary cells in several fish species. However subsequently the 418 
authentic GHRH genes were discovered in teleosts and amphibians [13]. Unlike PACAP, P. 419 
olivaceus PRP fails to regulate intracellular cyclic adenosine monophosphate (cAMP) production in 420 
Hirame natural embryonic cells (HINAE) transfected to over express the PAC-1 mRNA, and does 421 
not up-regulate PAC-1 transcript expression [29]. A PRP-specific receptor has yet to be cloned in 422 
that specie; in fact, PRP receptor has been isolated only from few species [13,24,25] and therefore, 423 
the biological activity of PRP in many aspects remains to be fully elucidated [29]. 424 
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In this study, comparative expression profiles of the two PACAP splicing variants and VIP/PACAP 425 
receptors were studied after viral (VHSV-Ia) and bacterial (Y. ruckeri) infection. VHSV is a 426 
negative single stranded RNA virus that causes a serious systemic hemorrhagic septicaemia in a 427 
wide variety of wild and cultured fish species, posing a major threat to the development of salmonid 428 
aquaculture [33–35]. PACAP was predominantly found to be induced during the early stages of the 429 
viral infection, while irregular expression patterns were observed for the receptors. The PACAP 430 
receptors expression modulation was mainly limited to the kidney, but a high individual variance 431 
confounded the analysis due to private response patterns. 432 
In mammals, VIP and PACAP have well-characterized effects on the immune system and anti-433 
inflammatory properties, including inhibition of macrophage adherence and down-regulation of 434 
inflammatory cytokines and production of reactive oxygen species [55]. Moreover, they can induce 435 
the production of anti-inflammatory cytokines such as IL-10 and β-chemokines, indeed upregulated 436 
during the inflammation playing a protective action by downregulating of pro-inflammatory 437 
cytokines [67–70]. Due to their immunomodulatory properties, both neuropeptides have been 438 
considered as promising therapeutic agents for a range of pathologies [71–74]. Their involvement in 439 
heterogeneous viral infections has been demonstrated [75–78]. For example, PACAP has potent 440 
regulatory activity on Herpes simplex virus activation [75], with increased plasma PACAP-38 441 
levels observed in patients with chronic hepatitis B following lamivudine-induced elimination of 442 
viraemia [76], and increased antiviral immunity was seen in the absence of VIP [77]. Treating HIV-443 
1-infected macrophages with VIP and PACAP diminished viral production, and treatment with 444 
specific agonists of the neuropeptide receptors VPAC-2 and PAC-1 showed similar effects. VIP 445 
promoted HIV-1 inhibition through stimulation of the receptors VPAC-1 and VPAC-2 but not 446 
through stimulation of PAC-1. The ability of PACAP to diminish HIV-1 replication, on the other 447 
hand, resulted from its ligation of all three receptors since its effect was only abrogated when all 448 
three were blocked. The mechanisms underlying these effects seem to be related to the regulation of 449 
the chemokine axis but also implicate induction of IL-10 secretion by macrophages [70,78]. 450 
The expression of genes encoding for PACAP and PRP, as well as for their affine receptors, was 451 
also studied after infection with Y. ruckeri. This Gram-negative bacterium is the aetiological agent 452 
of Yersiniosis or ERM, that still causes significant economic losses in salmonid aquaculture 453 
worldwide [79]. Although PACAP had higher levels of expression, both splicing variants were 454 
found to be consistently and highly induced, peaking during the early stages of the bacterial 455 
infection, with a predominant induction in the spleen and, as occurs after viral challenge, irregular 456 
expression patterns were observed for the receptors. Transcriptional regulation of PACAP splicing 457 
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variants after bacterial infection has been rarely studied and no previous reports exist on 458 
VIP/PACAP receptors transcriptional regulation after bacterial challenge in teleost fish. Only one 459 
report studied transcriptional regulation of the PRP/PACAP precursor in P. olivaceus challenged 460 
with the bacterial pathogen E. tarda [29]. PRP/PACAP precursor expression appeared in gut tissue, 461 
such as the intestine and pyloric caecum, in challenged but not in healthy fish. This pathogenic 462 
bacterium commonly resides in the fish intestine, where the epithelium of the gastrointestinal tract 463 
is the main site of attachment. Expression of the longer (PRP-containing) transcript gradually 464 
increased in the intestine of the bacteria-challenged flounder, suggesting an immunological role for 465 
these molecules, especially in the gastrointestinal tract [29]. Recently, the possible role of PACAP 466 
under LPS challenge was studied in grass carp [30]. The results showed that PACAP stimulated 467 
synthesis of pro-inflammatory cytokines (TNF-α and IL-1β) in head kidney, but affected neither 468 
expression of anti-inflammatory cytokine (IL-10) nor immune stimuli-induced expression (LPS or 469 
A. hydrophila stimuli) of the cytokines, implying that PACAP may not play an anti-470 
proinflammatory role in grass carp unlike in mammals. This discrepancy reflects the different roles 471 
of PACAP in mammals and fish with LPS challenge, but the possibility that it may be caused by 472 
different cell models and species variability is not excluded [30], thus further experiments are still 473 
required to clarify the involving of PACAP in inflammatory response in teleost fish.. In terms of the 474 
receptor expression, in our study VPAC-2 seems to be more actively regulated by bacterial 475 
infection compared with PAC-1 and VPAC-1, in agreement with results in mammals where 476 
expression of VPAC-2 in macrophages was reported to be up regulated by components of Gram-477 
negative bacteria such as TLR-4 ligands [80]. 478 
 479 
5. Conclusions 480 
This study reports for the first time the transcriptional modulation of PACAP gene splicing variants 481 
and VIP/PACAP receptors in brown trout (Salmo trutta). The expression of PACAP and PRP, as 482 
well as for the receptors PAC-1 (PACAP affinity), VPAC-1 and VPAC-2 (VIP/PACAP affinity), 483 
was comparatively studied in 6 tissues to assess their constitutive expression levels in this species. 484 
Subsequently the kidney and spleen were screened for the relative expression of these PACAP-485 
system genes over the course of a viral (VHSV-Ia) and bacterial (Y. ruckeri, serotype O1 biotype 2) 486 
septicaemic infections. Both PACAP and PRP were strongly induced during the pathogenesis of 487 
both diseases, although with specific patterns. A high individual variance confounded the 488 
transcriptomic analysis of PAC-1, VPAC-1 and VPAC-2 receptors, due to the presence of private 489 
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response patterns. Nevertheless, PAC-1 was found to have a late upregulation (after 2 weeks p.i.) in 490 
both disease states, while VPAC-2 showed a selective modulation in the kidney. Overall the results 491 
obtained from brown trout during this study provide more data as to how and when the PACAP 492 
system is modulated in teleosts, in this case during immune responses elicited by septicaemic 493 
infections. Nevertheless, further experimental evidence is still required to more fully characterize 494 
their involvement and precise role in protective immune responses to viral and bacterial pathogens. 495 
 496 
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Tables 736 
Table 1. Brown trout Salmo trutta sequence references, primers, amplicon sizes, specific RT-737 
qPCR conditions for genes expression screened during this study. Additional PRP intron 4 738 
sequence obtained with Accession Number HG000279. *Note: a common reverse primer to both 739 
splicing variants is used for PACAP detection. 740 
 741 
 742 
Table 2. PACAP and PRP ligands and VIP/PACAP receptors gene transcription correlation 743 
to infection markers. Pearson product-moment correlation coefficients (r), with their respective p 744 
values (2-tailed) given for correlations between individual gene expression and individual pathogen 745 
burden. Significant correlations are shown in bold; *p < 0.05; **p < 0.01 (2-tailed). Time*pathogen 746 
burden = p value based on Fisher's F-distributions using GLM analysis (ANCOVA) of specific gene 747 
expression to assess the significance of the interaction between days p.i., with the effect of 748 
individual pathogen burden as covariate. 749 
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Figures 760 
Fig. 1. Constitutive expression profiles of brown trout PACAP and PRP ligands and 761 
VIP/PACAP receptors genes, detected by RT-qPCR: (A) PACAP system ligands: PACAP and 762 
PRP; (B) VIP/PACAP receptors: PAC-1, VPAC-1 and VPAC-2. Tissues were sampled from 6 763 
healthy fish. Transcript concentrations were calculated using a standard curve specifically obtained 764 
for each primer pair. Data are normalised to the expression of a reference gene, EF-1α, and 765 
presented as group means + SEM. 766 
 767 
Fig. 2. Pathogen burden assessed on cDNA samples from brown trout kidney and spleen 768 
tissues. (A) Viral burden assessed by RT-qPCR targeting the VHSV transmembrane glycoprotein 769 
gene; (B) Bacterial burden assessed by RT-qPCR targeting the Y. ruckeri 16S rRNA. Results are 770 
obtained from individual kidney and spleen cDNAs and presented as mean fold change + SEM 771 
normalised to a Salmo trutta reference gene, EF-1α. 772 
 773 
Fig. 3. Expression kinetics of PACAP and PRP genes in kidney and spleen of VHSV-Ia and Y. 774 
ruckeri infected brown trout: (A; B) PACAP; (C; D) PRP. RT-qPCR detected transcript levels 775 
were normalised to the expression of a reference gene, EF-1α, and presented as group means + 776 
SEM. The p value of a LSD post hoc test between the pathogen infected group and the 777 
corresponding control (not shown in the graph) is shown above the bars as: *p < 0.05; **p < 0.01. 778 
 779 
Fig. 4. Expression kinetics of VIP/PACAP receptor genes in kidney and spleen of VHS-Ia and 780 
Y. ruckeri infected brown trout: (A; B) PAC-1; (C; D) VPAC-1; (E; F) VPAC-2. RT-qPCR 781 
detected transcript levels were normalised to the expression of a reference gene, EF-1α, and 782 
presented as group means + SEM. The p-value of a LSD post hoc test between the VHS infected 783 
group and the corresponding control (not shown in the graph) is shown above the bars as: *p < 0.05; 784 
**p < 0.01. 785 
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Table 1. Brown trout Salmo trutta sequence references, primers, amplicon sizes, specific RT-qPCR conditions for genes expression screened 
during this study. 
 
 
 
Additional PRP intron 4 sequence obtained with accession number HG000279. *Note: a common reverse primer to both splicing variants is used 
for PACAP detection. 
 
 
EF-1α HF563594 EF-1α-F CAAGGATATCCGTCGTGGCA EF-1α-R ACAGCGAAACGACCAAGAGG 327 63 30 88
PACAP HG000281 PACAP-F GGAGAAAAGTGGAGGGAGCA PRP/PACAP-R * TGTCTATACCTTTTCCCAAGGACTG 153 62 18 85
PRP HG000280 PRP-F2 CCACCGGAGAAAAGAACGGA PRP-R2  GCTTTGCCATCAGAGAATGGAG 112 64 18 82
PAC-1 HG000282 PAC1-F2 CTGCTTCTTACACACTGTGGAGTG PAC1-R2 CATATCCCAACACCCTATGTCA 244 62 22 83
VPAC-1 HG000283 VPAC1-F2         GTCCAACCAGTACTTGAGGCTG VPAC1-R3 CAACCGCAAATCCCTGGAATG 158 64 18 86
VPAC-2 HG000284 VPAC2-F2         GTGCTGGGAGAGGAATGACATC VPAC2-R2         GACTTAGCCAGACGCCTGTATTG 177 63 18 84
VHSV-Gp JN180851 VHSV G 1018 F CTCATTTCTCCTCTCAAAGTTTCG VHSV G 1018 R CCGTCTGTGTTGTTGTCTACC 192 60 18 86
Y. ruckeri  16S 
rRNA
EU401667 16S F GCGAGGAGGAAGGGTTAAGTG 16S R GAAGGCACCAAGGCATCTCT 589 63 30 87
Gene
GenBank Accession 
number
RT-qPCR conditions
Ta Te Mt
Forward primer (5’ to 3’) Reverse primer (5’ to 3’)
Amplicon 
size (bp)
Table 1
Table 2. PACAP system gene transcription correlation to the viral and bacterial burden and influence of time. 
 
Pearson product-moment correlation coefficients (r), with their respective p values (2-tailed) given for correlations between individual gene 
expression and individual pathogen burden. Significant correlations are shown in bold; *p < 0.05; **p < 0.01 (2-tailed). Time*pathogen burden = 
p value based on Fisher's F-distributions using GLM analysis (ANCOVA) of specific gene expression to assess the significance of the interaction 
between days p.i., with the effect of individual pathogen burden as covariate. 
 
 
Kidney Spleen Kidney Spleen Kidney Spleen Kidney Spleen
PACAP .736** .818** .822 .000 .397** .690** .000 .000
PRP .342* .566** .163 .001 .170 .240 .101 .001
PAC-1 .039 -.227 .007 .304 .032 -.365* .154 .002
VPAC-1 -.143 -.255 .008 .006 .108 .021 .291 .316
VPAC-2 .103 -.298* .009 .026 .461** -.091 .000 .085
Correlations Analysis
Gene Vs Viral burden 
(Pearson's r)
Time*Viral burden (p value)
Gene Vs Bacterial burden  
(Pearson's r)
Time*Bacterial burden (p 
value)
Table 2
